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Natural killer (NK) cells are innate lymphocytes
that possess adaptive features, including antigen-
specific clonal expansion and long-lived memory re-
sponses. Although previous work demonstrated that
type I interferon (IFN) signaling is crucial for NK cell
expansion and memory cell formation following
mouse cytomegalovirus (MCMV) infection, the global
transcriptional mechanisms underlying type I IFN-
mediated responses remained to be determined.
Here, we demonstrate that among the suite of tran-
scripts induced in activated NK cells, IFN-a is neces-
sary and sufficient to promote expression of its
downstream transcription factors STAT1, STAT2,
and IRF9, via an auto-regulatory, feedforward loop.
Similar to STAT1 deficiency, we show that STAT2-
or IRF9-deficient NK cells are defective in their ability
to expand following MCMV infection, in part because
of diminished survival rather than an inability to
proliferate. Thus, our findings demonstrate that indi-
vidual ISGF3 components are crucial cell-autono-
mous and non-redundant regulators of the NK cell
response to viral infection.
INTRODUCTION
Natural killer (NK) cells are innate lymphocytes that are critical for
tumor immunosurveillance and control of herpesvirus infections.
NK cell activation is determined by the balance of germline-
encoded inhibitory receptors, which recognize major histocom-
patibility complex (MHC) class I (i.e., ‘‘self’’), and activating
receptors that recognize stressed or infected cells, often in the
context of diminished MHC class I (i.e., ‘‘missing self’’) (Lanier,
2008). Upon activation, NK cells rapidly proliferate and release
pro-inflammatory cytokines such as IFN-g and cytotoxic mole-
cules (granzyme B) to lyse transformed or infected target cellsCell Re
This is an open access article under the CC BY-N(Sun and Lanier, 2011). Although they have traditionally been
classified as part of the innate immune system, NK cells are
now appreciated to share many features with adaptive lympho-
cytes, including clonal expansion, longevity, and robust recall
responses (Geary and Sun, 2017). One of the most well charac-
terized models of ‘‘adaptive’’ NK cell responses occurs during
mouse cytomegalovirus (MCMV) infection. The MCMV-encoded
glycoprotein m157 is specifically recognized by the Ly49H
receptor expressed on a subset of NK cells in C57BL/6 mice,
and receptor-ligand engagement drives rapid NK cell prolifera-
tion and effector functions that provide resistance to MCMV
(Arase et al., 2002; Brown et al., 2001; Daniels et al., 2001; Dokun
et al., 2001; Smith et al., 2002). Following their rapid expansion,
virus-specific NK cell effectors contract to form a long-lived pool
of memory cells that exhibit enhanced effector functions upon
secondary challenge (Sun et al., 2009).
Previous studies have demonstrated that pro-inflammatory
cytokine signals, particularly IL-12 and type I interferon (IFN),
are crucial for NK cell expansion and memory formation (Madera
et al., 2016; Sun et al., 2012). Canonical type I IFN signaling
requires TYK2 and JAK1-mediated phosphorylation of STAT1
and STAT2, which then form a heterotrimer with IRF9. This com-
plex, termed ISGF3, translocates to the nucleus, where it binds
to IFN-stimulated response elements (ISRE) to promote expres-
sion of hundreds of IFN-stimulated genes (ISGs) encoding pro-
teins with antiviral functions (Ivashkiv and Donlin, 2014). It is
thought that specificity for the ISRE sequence is provided by
IRF9, while additional DNA contacts with STAT1 and STAT2 sta-
bilize the interaction, and STAT2 provides the transcriptional
activation domain (Bluyssen and Levy, 1997; Levy et al., 1989;
Qureshi et al., 1995; Veals et al., 1993; Wesoly et al., 2007). How-
ever, there is increasing evidence that alternative complexes,
containing unphosphorylated STATs or different combinations
of STATs with or without IRF9, also form in response to type I
IFN stimulation and may contribute to the pleiotropic biological
effects of IFNs (reviewed in Fink and Grandvaux, 2013; Majoros
et al., 2017). The biological importance of these alternative path-
ways has been demonstrated by studies showing that Stat2/
or Irf9/ mice were more resistant to certain viral infectionsports 24, 1949–1957, August 21, 2018 ª 2018 The Author(s). 1949
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
than Stat1/mice (Hofer et al., 2012; Perry et al., 2011) and that
STAT1-independent transcription of some ISGs can be driven by
STAT2 or IRF9 (Luker et al., 2001; Perry et al., 2011). Thus, we
sought to better understand the global transcriptional mecha-
nisms underlying type I IFN-mediated responses of NK cells dur-
ing viral infection and whether these pathways are directly
controlled by canonical ISGF3 signaling.
RESULTS AND DISCUSSION
Type I IFN Signaling in NK Cells Induces Auto-regulation
of ISGF3 Components
To investigate the genes induced by type I IFNs in NK cells,
we performed comparative transcriptome analysis by RNA-
sequencing (RNA-seq) on purified NK cells that were stimulated
with IFN-a or left unstimulated (media alone). The vast majority of
transcriptional changes were induced by IFN stimulation, and
the most highly induced genes included many canonical ISGs,
such as Ifit3, Rsad2, and Isg15 (Figure 1A). Among the genes
significantly induced by IFN-a in NK cells, chromatin immuno-
precipitation sequencing (ChIP-seq) demonstrated that 32%
were bound by STAT1. Interestingly, themost highly differentially
expressed genes were not preferentially STAT1 bound (Fig-
ure 1B). Among the top STAT1-bound, IFN-a-induced transcrip-
tion factors were several genes known to be important for the NK
cell response to MCMV, such as Runx3 (Rapp et al., 2017) and
Tbx21 (Madera et al., 2018), as well as all three ISGF3 compo-
nents (Figure 1C). Analysis of the individual Stat1, Stat2, and
Irf9 loci confirmed that NK cells exposed to IFN-a significantly
induced transcription of these genes (Figure 1D). Furthermore,
STAT1 targeted the promoters of all three ISGF3 components
(Figure 1E). Thus, we propose that STAT1 (and other ISGF3 com-
ponents) may operate in an auto-regulatory manner in NK cells
during viral infection.
NK Cells Demonstrate IFN-Induced, but
STAT1-Independent, Transcriptional Changes during
Viral Infection
To determine if all genes inducedduring type I IFN exposurewere
dependent on STAT1 signaling for their expression in vivo, we
performed RNA-seq on wild-type (WT), Ifnar1/, and Stat1/
Ly49H+ NK cells from MCMV-infected and uninfected mixed
bone marrow chimeric mice (mBMCs) (Figure 2A). We observed
872 differentially expressed genes between WT and Ifnar1/
NK cells (Figure 2B) and 838 differentially expressed genes be-
tweenWTandStat1/NKcells (Figure 2C) at day 1.5 post-infec-
tion (PI). Many of the most significant changes were canonical
ISGs (e.g., Irf7, Rtp4, Mx1) that were induced ex vivo and com-
monbetweenboth knockouts. Interestingly, themajority of differ-
entially expressed genes did not overlap with our list of genes
induced by IFN-a ex vivo. Importantly, we found that after
MCMV infection, expression of all three ISGF3 components
was upregulated in WT Ly49H+ NK cells, but this increase was
almost completely abolished in the absence of STAT1 (Figure 2D)
or the type I IFN receptor (Figure S1A). These findings are consis-
tent with the auto-regulatory mechanism proposed above and
also suggest that ISGF3 components operate in a feedforward
manner to promote their own transcription.1950 Cell Reports 24, 1949–1957, August 21, 2018Although the transcriptional profile of IFNAR1- and STAT1-
deficient NK cells appeared similar at the global level, direct
comparison of genes revealed that fewer than 60% of the differ-
entially expressed transcripts were common to both knockouts
relative to WT NK cells (Figures 2E and S1B–S1E). The dysregu-
lated genes unique to Stat1/ NK cells could be due to down-
stream influences of other cytokine signaling pathways that
have been proposed to induce phosphorylation of STAT1
(e.g., IFN-g or IL-21); however, the transcriptional changes
unique to Ifnar1/ NK cells suggest that non-canonical type I
IFN signaling pathways may be active in NK cells during viral
infection.
Individual ISGF3 Components Promote Clonal
Expansion of Antiviral NK Cells in a Cell-Autonomous
and Non-redundant Manner
This noncongruent transcriptomic profile of Ifnar1/ versus
Stat1/NK cells led us to hypothesize that IRF9, and potentially
STAT2, may also play important, non-redundant roles in the
response of NK cells to MCMV infection. Because both
Ifnar1/ and Stat1/ mice are highly susceptible to MCMV
(Gil et al., 2001), we determined whether IRF9 is also required
for host control of MCMV infection. We challenged WT and
Irf9/mice with MCMV and found that Irf9/mice were unable
to control the infection, resulting in higher viral titers in the blood
(Figure S2A) and early death (Figure S2B).
To more directly interrogate the importance of IRF9 and
STAT2 in NK cells, we investigated whether any effector func-
tions of NK cells were abrogated in the absence of these factors.
During MCMV infection, activated Ly49H+ NK cells proliferate
to expand the pool of effector cells (Dokun et al., 2001; Sun
and Lanier, 2011). To test the role of IRF9 in the expansion of
MCMV-specific NK cells, we co-transferred equal numbers of
WT (CD45.1) and Irf9/ (CD45.2) Ly49H+KLRG1lo NK cells
into Ly49H-deficient recipients, and following MCMV infection,
we tracked the expansion of the transferred Ly49H+ NK cells
(Figure 3A). In contrast to WT NK cells, which underwent robust
expansion, IRF9-deficient NK cells expanded modestly and rep-
resented a smaller proportion of the effector andmemory NK cell
pools (Figures 3B and 3C). STAT2-deficient NK cells showed a
similar defect in expansion and contribution to the memory cell
pool after MCMV infection (Figures 3D and 3E). Together, these
findings demonstrate a non-redundant requirement for all ISGF3
components in promoting NK cell expansion following viral
infection.
As has been previously reported for Ifnar1/ mice (Guan
et al., 2014; Mizutani et al., 2012), we observed minor defects
in NK cell development in the global absence of IRF9 and
STAT2 (Figures S3A–S3C; data not shown). To confirm that the
expansion defects we observed were due to cell-intrinsic roles
for IRF9 and STAT2 during MCMV infection, we generated
mBMC by reconstituting irradiated mice with bone marrow
from Irf9/ or Stat2/ and WT mice. In this setting, both
IRF9- and STAT2-deficient NK cells repopulated the mice with
similar efficiency to WT NK cells (Figure S3D; data not shown),
and the knockout cells that arose were phenotypically indistin-
guishable from WT NK cells (Figure S3E; data not shown), sug-
gesting that the developmental defects observed in NK cells
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Figure 1. The NK Cell Interferome Reveals Auto-regulation of ISGF3 Components
Splenic NK cells were sort purified and cultured overnight with IFN-a and assayed using RNA-seq and aSTAT1 ChIP-seq. Cells cultured in media alone served as
controls for RNA-seq.
(A) Heatmap depicting row-normalized log2-transformed counts of differentially expressed genes with absolute log2fold change > 1 and false discovery rate -
adjusted p value (FDR) < 0.05 calculated using DESeq2. Genes of interest are labeled.
(B) Volcano plot of RNA-seq data from ex vivo stimulated NK cells. Blue dots show differentially expressed (FDR < 0.05) genes bound by STAT1 as determined by
ChIP-seq. Horizontal line indicates p = 0.05, and vertical lines show absolute log2 fold change = 1.
(C) Bar graph depicts fold enrichment of STAT1 binding over input calculated by MACS2. Shown are the top 20 peaks ranked by fold enrichment that are
associated with differentially expressed transcription factors as determined by RNA-seq.
(D) Normalized counts of Stat1, Stat2, and Irf9 in splenic NK cells unstimulated or cultured overnight with IFN-a assessed using RNA-seq. Symbols represent
biological replicates, and error bars show SEM (*p < 0.05).
(E) Representative gene tracks from STAT1 ChIP-seq showing counts on y axis and genomic coordinates on x axis. RNA-seq is two biological replicates. ChIP-
seq is two independent experiments of 20–25 pooled mice per experiment.directly isolated from the Irf9/ or Stat2/ mice were cell
extrinsic. When WT and IRF9- or STAT2-deficient cells were
adoptively transferred from mBMC into Ly49H-deficient mice,
we observed a similar expansion defect in knockout NK cells
following MCMV infection (data not shown).
A major function of NK cells during viral infection is to produce
pro-inflammatory cytokines such as IFN-g, in addition to medi-
ating cytotoxicity. In uninfected mice, WT and Irf9/ NK cells
showed comparable IFN-g production and degranulation afterex vivo stimulation (Figure S3F; data not shown) and killed
m157-expressing target cells similarly (Figure S3G), suggesting
that IRF9 does not play a critical role in the acquisition of NK
cell effector functions during development. However, during
MCMV infection, Irf9/ NK cells failed to upregulate granzyme
B to the same extent as WT cells (Figure 3F), although they
expressed similar levels of IFN-g (Figure 3G) and activation
markers (Figures 3H and 3I). Thus, defects in expansion and
expression of cytolytic molecules by Irf9/ NK cells likelyCell Reports 24, 1949–1957, August 21, 2018 1951
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Figure 2. During MCMV Infection, a Subset of IFNAR1-Dependent Transcriptional Changes in NK Cells Are STAT1 Independent
(A) Schematic of experimental design. Briefly, mBMC mice harboring both WT and Ifnar1/ or WT and Stat1/ NK cells were infected with MCMV. Splenic
Ly49H+ NK cells of each genotype were sorted for RNA-seq at 0 and 1.5 days PI (n = 1–3 per genotype per time point).
(B) Volcano plot of RNA-seq data comparing Ifnar1/ andWTNK cells at day 1.5 PI. IFNa-inducible genes (i.e., differentially expressed genes in Figure 1) that are
also differentially expressed in Ifnar1/ versus WT NK cells are shown in blue, with select genes highlighted. Number of blue genes of total differentially
expressed between Ifnar1/ and WT NK cells at day 1.5 PI genes indicated at upper right.
(C) As in (B) but showing Stat1/ versus WT.
(D)NormalizedcountsofStat1,Stat2, and Irf9 inWTandStat1/NKcells fromRNA-seq.Symbols representbiological replicates,anderrorbars showSEM(*p<0.05).
(E) Overlap of differentially expressed genes between WT and Ifnar1/ versus WT and Stat1/ NK cells at day 1.5 PI.contribute to the increased susceptibility of Irf9/ mice to
MCMV infection. However, because Irf9/NK cells can still pro-
duce IFN-g, this may afford the Irf9/ mice some degree of
protection.
IRF9 Promotes Survival but not Proliferation of NK Cells
following Viral Infection
To determine how IRF9 deficiency impaired NK cell expansion,
we performed comparative transcriptome analysis by RNA-seq
on purified WT and Irf9/ Ly49H+ NK cells from mBMC 4 days
post-MCMV infection, a time point immediately after Irf9 expres-
sion peaks in WT cells (Figure 2D). The absence of IRF9 altered
the expression of 1,008 genes (Figure 4A). Although similar
numbers of genes were induced and repressed by IRF9, the
most significant changes occurred in genes found to be downre-
gulated in Irf9/ cells relative to WT cells, and many of these1952 Cell Reports 24, 1949–1957, August 21, 2018were canonical ISGs (Figure 4A). Pathway analysis showed dys-
regulation of IFN signaling pathways (Figure S4A) but also
revealed alterations in apoptosis signaling and lymphocyte acti-
vation pathways (Figure 4B). Labeling NK cells with the division-
tracking dye CTV prior to adoptive transfer confirmed that IRF9
was dispensable for MCMV-driven NK cell proliferation (Fig-
ure 4C). In contrast, FLICA staining (to detect activated cas-
pases) showed evidence of greater apoptosis in Irf9/ NK cells
(Figure 4D). Together, these findings suggest that IRF9 is
required for NK cell survival, but not proliferation, following
MCMV infection.
Previous studies have shown that IFNAR1-deficient lympho-
cytes are susceptible to killing by activated NK cells after viral
infection because of lower expression of MHC I and higher
expression of ligands for NK cell activating receptors (Crouse
et al., 2014; Madera et al., 2016; Xu et al., 2014). Consistent
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Figure 3. Non-redundant and Cell-Intrinsic Requirement for ISGF3 Components for the Optimal Expansion of Antiviral NK Cells
(A) Experimental schematic. Equal numbers of splenic Ly49H+ KLRG1lo NK cells fromWT (CD45.1) and Irf9/ or Stat2/mice (CD45.2) were co-transferred into
Ly49H-deficient recipients prior to infection with MCMV.
(B) Absolute percentages of adoptively transferred WT versus Irf9/ Ly49H+ NK cells measured in peripheral blood at the indicated times following MCMV
infection or inferred from transfer (day 0).
(C) Relative percentage of transferred WT and Irf9/ Ly49H+ NK cells in indicated organs at day 28 PI.
(D) As in (B), except that NK cells were transferred from WT and Stat2/ mice.
(E) As in (C), except that NK cells were transferred from WT and Stat2/ mice.
(F) Expression of intracellular granzyme B in splenic WT and Irf9/ Ly49H+ NK cells from mBMC animals on day 2 PI with MCMV.
(G) As in (F), except showing IFN-g.
(H and I) KLRG1 (H) and CD27 and CD11b (I) expression were assessed in the blood 7 days PI with MCMV following co-adoptive transfer of WT and Irf9/ cells,
as in (B).
Data are representative of two (D–G) or three (B, C, H, and I) independent experiments with n = 3–5 mice per group. Symbols represent mean (B and D) or
individual mice (C and E–G), and error bars show SEM (*p < 0.05).
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Figure 4. IRF9 Is Required for Survival but Not Proliferation of NK Cells following Viral Infection
mBMC mice harboring both WT and Irf9/ NK cells were infected with MCMV. Splenic Ly49H+ WT and Irf9/ NK cells were sorted for RNA-seq at 4 days PI
(n = 3 per genotype).
(A) Volcano plot of RNA-seq data showing differentially expressed genes with genes of interest labeled. Horizontal line indicates p = 0.05, and vertical lines show
absolute log2 fold change = 1.
(B) Top five enriched pathways as calculated using the PANTHER database, including number of differentially expressed genes per pathway and names of
representative genes. Bar plots depict log10 p values calculated using goseq.
(C) As in Figure 3A, except NK cells were labeled with CTV prior to adoptive co-transfer. Left: representative histogram of CTV in splenicWT and Irf9/ Ly49H+NK
cells at day 3 PI. Right: quantification of Ly49H+ NK cells that divided more than once.
(D) Pan-caspase activation in transferred Ly49H+ NK cell populations in the spleen at day 4 PI.
(E) Heatmap of row-normalized log2-transformed counts of differentially expressed genes with putative roles in NK cell activation or inhibition. Experimentally
validated activating ligands are green and experimentally validated inhibitory ligands are red.
(F)WT and Irf9/NK cells were co-transferred into Ly49H-deficient recipients as in Figure 3A or transferred intoRag2/IL2rg/mice orNKp46Cre R26DTAmice.
Data are representative of three independent experiments with n = 2–5 mice per group. Symbols represent individual mice, and error bars show SEM (*p < 0.05).
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with these findings, our RNA-seq analysis revealed that Irf9/
NK cells also have dysregulated expression of known and puta-
tive ligands for activating and inhibitory NK cell receptors
following MCMV infection (Figure 4E), which may contribute to
overall susceptibility to cytotoxicity. Specifically, Irf9/ NK cells
showed higher expression of Clec2i, which encodes Clr-g, a
ligand for the activating receptor NKRP1f (Iizuka et al., 2003),
and lower expression of several MHC class I molecules,
including H2-t23, encoding the MHC class Ib molecule Qa-1b,
which is critical for protecting activated T cells from lysis by
NKG2A+ NK cells (Lu et al., 2007). Furthermore, of the molecules
affected by IRF9 ablation, ChIP-seq showed that four of the nine
genes had IRF9 binding to their promoters in NK cells stimulated
with IFN-a (Figure S4B), suggesting direct IRF9-mediated regu-
lation of these loci.
Previous work demonstrated that depletion of NK cells
or transfer into NK cell-deficient hosts was sufficient to
rescue the expansion defect of Ifnar1/ T and NK cells (Crouse
et al., 2014; Madera et al., 2016; Xu et al., 2014). Likewise,
we found that following transfer into lymphocyte-deficient
Rag2/IL2rg/ mice or NK cell-deficient (NKp46Cre R26DTA)
mice, Irf9/ cells expanded comparably with WT NK cells
following MCMV infection (Figure 4F). Although the co-trans-
ferred WT NK cells in this setting are likely capable of fratricide,
we hypothesized that they are not present in sufficient numbers
to mediate appreciable levels of killing. Furthermore, Irf9/ NK
cells showed higher levels of cell death relative to WT NK cells
when co-incubated with high ratios of activated effector NK cells
(Figure S4C). Thus, IRF9-dependent sensing of type I IFNs
during viral infection is necessary to protect activated NK cells
against elimination by neighboring (host) NK cells.
In summary, we identified the total set of genes induced by
IFN-a stimulation of purified NK cells and found that a subset
of these genes, including Stat1, Stat2, and Irf9, were also
induced during MCMV infection in a manner dependent on
type I IFN signaling, suggesting an auto-regulatory loop in NK
cells to support robust IFN-dependent antiviral responses. We
used IRF9- and STAT2-deficient mice to demonstrate a non-
redundant requirement for all three ISGF3 components in NK
cell expansion and memory cell formation after MCMV. NK cells
deficient in the type I IFN pathway proliferate normally but have
dysregulated cell death pathways and altered expression of
NK cell receptor ligands, making them susceptible to NK cell-
mediated fratricide.
It is well established that NK cell cytotoxicity is triggered
by weighing the balance of activating and inhibitory inputs
(Joncker et al., 2009). Although NK cells have been shown to
tolerate a wide range of MHC class I levels (Brodin et al.,
2010; Jonsson et al., 2010), their tolerance of low levels of
MHCI is significantly reduced in inflammatory settings (Ludigs
et al., 2015; Sun and Lanier, 2008). Thus, it may not be surpris-
ing that subtle shifts in expression of a handful of cell surface
molecules (activating and inhibitory ligands) would be causative
of larger defects in the ability of ISGF3 component-deficient
NK cells to expand following MCMV infection. We speculate
that it is the combined impact of increased activating ligand
and reduced MHC class I expression on proliferating Irf9/
NK cells together with the heightened cytotoxic function ofneighboring (WT host) NK cells that leads to fratricide during
the antiviral response.
Previous studies have shown that expression of ISGF3
components increases following treatment of cells with IFNs
or other cytokines and that this heightened expression can
augment the induction of downstream ISGs (Ivashkiv and Donlin,
2014). However, this evidence has primarily been demonstrated
in cell lines or macrophages stimulated with IFN-g; here, we
demonstrate that type I IFN signaling in primary lymphocytes is
both necessary and sufficient to induce Stat1, Stat2, and Irf9
expression in vitro and in vivo through an auto-regulatory mech-
anism. Such transcriptional auto-regulatory loops have been
described across a range of systems and are important control-
lers of diverse processes ranging from bacterial pathogenicity
(Zhang et al., 2013) to neuronal development (Bai et al., 2007)
and cell cycle progression in eukaryotes (Johnson et al., 1994).
That ISGF3 components in the mammalian immune system are
also regulated in this manner likely allows lymphocytes to
respond rapidly at the first sign of infection and highlights the
importance of the type I IFN pathway in the host immune
response.
Although our transcriptomic data were suggestive that non-
canonical type I IFN signaling complexes might be activated in
NK cells during viral infection (Figure 2E), adoptive transfer
experiments with NK cells deficient in any member of the
ISGF3 complex, or the upstream receptor, had a similar pheno-
type (i.e., an expansion defect due to fratricide). Thus, our data
neither prove nor disprove the existence of non-canonical type
I IFN signaling but demonstrate a critical, non-redundant func-
tion of individual ISGF3 components in antiviral NK cell defense.
Furthermore, our study suggests that the dominant roles of the
type I IFN pathway in NK cells during viral infection are to pro-
mote cytotoxicity (via upregulation of granzyme B) and protect
against fratricide by proper regulation of cell surface receptors
and ligands. Additionally, it is likely that other ISGs will have
important functions in NK cells that are being masked by the
overwhelming fratricide phenotype, and future studies are
needed to address the potential roles of the ISGs identified in
our ex vivo or in vivo experiments. A greater understanding of
the molecular mechanisms underlying IFN signaling in activated
lymphocytes will aid in our fight against a plethora of infectious
diseases.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All mice used in this study were housed and bred under specific pathogen-free conditions atMemorial Sloan Kettering Cancer Center
(MSKCC) in accordance with all guidelines of the Institutional Animal Care and Use Committee. This study used the following mouse
strains, all on the C57BL/6 genetic background: C57BL/6 (CD45.2; The Jackson Laboratory), B6.SJL (CD45.1; Taconic), Ifnar1/
(M€uller et al., 1994), Stat1/ (Meraz et al., 1996), Stat2/ (Park et al., 2000) (JAX stock #023309), Irf9/ (Kimura et al., 1996),
Klra8/ (Ly49H deficient; (Fodil-Cornu et al., 2008)), Nkp46iCre (referred to as NKp46Cre; (Narni-Mancinelli et al., 2011)), Rag2/
Il2rg/ (Taconic), and R26DTA (The Jackson Laboratory). NKp46Cre x R26DTA mice were generated at MSKCC. Experiments were
conducted using age- and gender-matched mice in accordance with approved institutional protocols. Animals were typically
6-10 weeks old at the time of use and consisted of males and females.
Virus
MCMV (Smith strain) was serially passaged through BALB/c hosts twice, then viral stocks were prepared by dissociating salivary
glands 3 weeks after infection with a dounce homogenizer.
Cell Lines
Ba/F3 cells were maintained at 37C in RPMI medium 1640 containing 10% FBS, 1mM sodium pyruvate, 2 mM glutamine, 1 mM
HEPES, and 100 mg/mL penicillin/streptomycin. Ba/F3-m157 (Voigt et al., 2003) were maintained in the same conditions with the
addition of 1 mM puromycin.
METHOD DETAILS
Mixed Bone Marrow Chimeras
Mixed bone marrow chimeric mice were generated by lethally irradiating (900 cGy) host CD45.1xCD45.2 mice, which were recon-
stituted with a 1:1mixture of bonemarrow cells fromWT (CD45.1) and genetic-deficient (CD45.2) donormice. Hostswere co-injected
with anti-NK1.1 (clone PK136) to deplete any residual donor or host mature NK cells. Host CD45.1+ CD45.2+ NK cells were excluded
from all analyses.
In vivo Virus Infection
Adoptive transfer studies were performed by mixing splenocytes from WT (CD45.1) and genetic-deficient (CD45.2) mice to achieve
equal numbers of Ly49H+KLRG1lo NK cells, and injecting intravenously into adult Ly49H-deficient mice 1 day prior to MCMV
infection. Recipient mice in adoptive transfer studies were infected by i.p. injection of 7.5 3 102 PFU of MCMV. Experimental
mixed bone marrow chimera mice were infected by i.p. injection of 7.53 103 PFU of MCMV. For survival studies, mice were infected
by i.p. injection of 4 3 104 PFU of MCMV.e3 Cell Reports 24, 1949–1957.e1–e6, August 21, 2018
Determination of Viral Titers
Viral titers were determined as previously described (Kamimura and Lanier, 2014). DNA was isolated from peripheral blood using
a genomic purification kit (QIAGEN). Following isolation, DNA concentration was measured using Nanodrop for each sample,
and 3 mL was added into mastermix containing iQ Sybr Green (Bio-Rad) and primers specific to MCMV IE-1 DNA (forward:
TCGCCCATCGTTTCGAGA, reverse: TCTCGTAGGTCCACTGACCGA). Copy number was determined by comparing Cq values to
a standard curve of known dilutions of an MCMV plasmid and normalizing relative to total DNA content.
Isolation of Lymphocytes
Spleens were dissociated using glass slides and filtered through a 100-mm strainer. To isolate lymphocytes from liver, the tissue was
physically dissociated using a glass tissue homogenizer and purified using a discontinuous gradient of 40% over 60% Percoll.
To isolate cells from the lung, the tissue was physically dissociated using scissors and incubated for 30 min in digest solution
(1 mg/mL type D collagenase in RPMI supplemented with 5% fetal calf serum, 1% L-glutamine, 1% penicillin-streptomycin, and
10 mM HEPES). Resulting dissociated tissue was passed through 100-mm strainers, centrifuged, and lymphocytes were removed
from the supernatant. To isolate bone marrow lymphocytes, cleaned femur and tibia bones were ground with mortar and pestle, and
the resulting solution filtered through a 100-mm strainer. To isolate the stromal vascular fraction (SVF) of adipose tissue, visceral
adipose tissue was physically dissociated using scissors and incubated for 40 min in digest solution (2mg/ml type II collagenase
in RPMI supplemented with 5% fetal calf serum, 1% L-glutamine, 1% penicillin-streptomycin, and 10 mM HEPES). Resulting
dissociated tissue was passed through 100-mm strainers, centrifuged, and adipocytes were removed from the supernatant. Red
blood cells in spleen, liver, lung, adipose and bone marrow were lysed using ACK lysis buffer.
Flow Cytometry and Cell Sorting
Cell surface staining of single-cell suspensions from various organs was performed using fluorophore-conjugated antibodies
(BD Biosciences, eBioscience, BioLegend, Tonbo, R&D Systems). Intracellular staining was performed by fixing and permeabilizing
with the eBioscience Foxp3/Transcription Factor Staining Set for staining intranuclear proteins and cytokines.
Flow cytometry and cell sorting were performed on the LSR II and Aria II cytometers (BD Biosciences), respectively. For RNA-Seq
experiments, cell population were sorted to > 95% purity. Data were analyzed with FlowJo software (Tree Star). Flow cytometry of
purified lymphocytes was performed using the following fluorophore-conjugated antibodies: CD3ε (17A2), TCRb (H57-597), CD19
(ID3), F4/80 (BM8.1), NK1.1 (PK136), Ly49H (3D10), CD45.1 (A20), CD45.2 (104), CD11b (M1/70), CD27 (LG.3A10), KLRG1 (2F1),
Ly49D (4E5), Ly49A (YE1/48.10.6), Ly49C/I (5E6), CD69 (H1.2F3), Granzyme B (GB11), IFN-g (XMG1.2), CD107a (1D4B), and
CD49b (DX5).
Apoptosis was evaluated by caspase activity staining using the carboxyfluorescein FLICA poly caspase assay kit (BioRad)
or Annexin V (BioLegend). NK cell proliferation was analyzed by labeling cells with 5 mMCell Trace Violet (CTV, Thermofisher) before
transfer, and CTV labeling was performed according to manufacturer protocol.
Ex vivo stimulation of Lymphocytes
Approximately 106 spleen lymphocytes were stimulated for 4 hr in RPMI containing 10% fetal bovine serum with 20 ng/mL recom-
binant mouse IL-12 (R&D Systems) plus 10 ng/mL IL-18 (MBL) or 50 ng/mL PMA (Sigma) plus 500 ng/mL Ionomycin (Sigma). Cells
were cultured in media alone as a negative control.
Ex vivo killing assay
To test the cytotoxic capacity of Irf9/NK cells, Ba/F3 target cells and Ba/F3-m157 control cells were labeled differentially with Cell
Trace Violet (CTV, Invitrogen), according to manufacturer protocol (Ba/F3, CTVlo; Ba/F3-m157, CTVhi). 53 103 of each cell line were
mixed with 5 3 104 purified NK cells from WT or Irf9/ mice, or without NK cells (control condition). Effector and target cells were
co-cultured for 6 hours at 37C in RPMI-1640 containing 10% FBS. After 6 hours, cells were stained with propidium iodide prior to
flow cytometry. Percentages of target cell killing were determined using the following formula (adapted from (Viant et al., 2017)):
100 - ([(% Ba/F3-m157 cells/% Ba/F3 cells)]/[(% Ba/F3-m157 cells/% Ba/F3 cells) control] 3 100). For this formula, only CTV+ cells
within live cells were considered. Percentage of PI+ target and control cells was determined from total CTVhi and CTVlo cells
respectively.
To test the ability of activated WT NK cells to directly kill Irf9/NK cells, NK cells were first enriched from spleens of pooledWT or
Irf9/mice by negative selection over BioMag goat anti-rat IgG beads (QIAGEN) coated with rat anti-mouse CD8a, CD4, CD19, and
Ter-119 antibodies (Bio X Cell, clones 2.43, GK1.5, 1D3, and TER-199 respectively). Enriched CD45.1+CD45.2+ WT NK cells were
used as effectors cells against a 1:1 mix of CD45.1+ WT and CD45.2+ Irf9/ NK cell targets. Effector and target cells were co-
cultured for 16 hours at 37C in RPMI-1640 containing 10% FBS and IL-2 (10 ng/mL), IL-12 (100 ng/mL), IL-18 (10 ng/mL), and
IFN-a (100U/mL). After 16 hours, cells were stained with Annexin V and Fixable Viability Dye (eBioscience) prior to flow cytometry;
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RNA Sequencing
To determine the transcriptome of NK cells following stimulation with IFN-a, NK cells (TCRb-CD19-CD3ε-F4/80-NK1.1+CD49b+) were
sorted from C57BL/6 mice, incubated overnight with 100 U/mL IFN-a or no cytokine (unstimulated), then 5-8 3 104 NK cells were
sorted again for purity. To determine the STAT1-, IFNAR1- and IRF9-dependent transcriptional events in NK cells during MCMV
infection, 1.5-10 3 104 Ly49H+ NK cells (TCRb-CD19-CD3ε-F4/80-NK1.1+Ly49H+) were sorted from spleens of individual mBMC
mice harboring WT (CD45.1) and IFN signaling-deficient (CD45.2) cells at d0, d2 or d4 PI with MCMV. RNA was isolated from sorted
cell populations using TRIzol (Invitrogen) and total RNA was amplified using the SMART-seq V4 Ultra Low Input RNA kit (Clontech).
Subsequently, 10 ng of amplified cDNAwas used to prepare Illumina HiSeq libraries with the Kapa DNA library preparation chemistry
(Kapa Biosystems) using 8 cycles of PCR. Samples were barcoded and run on Hiseq 2500 1T, in a 50bp/50bp paired-end run, using
the TruSeq SBS Kit v3 (Illumina).
Chromatin immunoprecipitation and DNA sequencing
5-10 3 106 NK cells (TCRb-CD19-CD3ε-F4/80-NK1.1+CD49b+) were sorted from spleens of pooled C57BL/6 mice and incubated
overnight (16-18 hours) with cytokines. NK cells were stimulated with 100 U/mL IFN-a with or without 10 ng/mL IL-2. DNA and pro-
teins were cross-linked for 8 minutes using 1% formaldehyde. ChIP was performed as previously described (Beaulieu et al., 2014;
Zheng et al., 2007), using 10 mg of rabbit polyclonal anti-STAT1 antibody (Santa Cruz, sc-592, clone M-22), or 10 mg of rabbit poly-
clonal anti-IRF9 antibody (Santa Cruz, sc-496, cloneC-20) followed by Illumina next-generation sequencing. Fragments between 100
and 600 bp were size selected and Illumina HiSeq libraries were prepared using the Kapa DNA library preparation chemistry (Kapa
Biosystems) and 12-15 cycles of PCR. Adaptors were diluted 1/10 or 1/50 depending on the starting amount of material available.
Barcoded libraries were run on Hiseq 2500 1T in a 50bp/50bp paired-end run, using the TruSeq SBS Kit v3 (Illumina). STAT1-ChIP
was performed twice, while IRF9-ChIP was performed 3 times.
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-Seq Analysis
Paired-end reads were trimmed for adaptors and removal of low quality reads using Trimmomatic (v.0.36)(Bolger et al., 2014).
Trimmed reads were mapped to the Mus musculus genome (mm10 assembly) using Bowtie2 (v2.2.9)(Langmead and Salzberg,
2012). Read counts overlapping exons according to the UCSC Known Gene model were generated using the summarizeOverlaps
function from the GenomicAlignments package (v1.10.1)(Lawrence et al., 2013). Differential analyses were executed with DESeq2
(v1.14.1)(Love et al., 2014). Genes were considered differentially expressed if they showed an FDR adjusted p value < 0.05, adjusted
for multiple hypothesis correction as calculated by the DESeq2 software. For gene set enrichment analysis, differentially expressed
genes were passed into goseq (v1.32.0) using the PANTHER and REACTOME databases. Top pathways were ranked by p-value,
selected only from those passing a threshold of FDR-corrected p < 0.05.
ChIP-Seq analysis and peak annotation
For STAT1-ChIP, paired-end reads were trimmed for adaptors and removal of low quality reads using Trimmomatic (v.0.36)(Bolger
et al., 2014). Trimmed reads were mapped to the Mus musculus genome (mm10 assembly) using Bowtie2 (v2.2.9)(Langmead and
Salzberg, 2012). Concordantly aligned paired mates were used for individual peak calling and pooled replicate peak calling by
MACS2 (v2.1.1.20160309)(Zhang et al., 2008) with the arguments ‘‘-p 1e-2 -m 2 50 –to-large.’’ Irreproducible discovery rate (IDR)(Li
et al., 2011) calculations using scripts provided by the ENCODE project (https://www.encodeproject.org/software/idr/; v2.0.2 and
v2.0.3) were performed on all pairs of individual replicate peak lists against the oracle peak list of pooled replicates. Reproducible
peaks were thresholded for those showing an IDR value of 0.05 or less and used for further analysis. Peak assignment to genes
and gene features was performed using ChipPeakAnno(Zhu et al., 2010). Promoter peaks were defined as peaks that overlapped
a region that was +2kb to 0.5kb from the transcriptional start site (TSS). Intragenic (intronic and exonic) peaks were defined as
any peak that overlapped with annotated intronic and exonic regions, respectively, based on the UCSC Known Gene annotation da-
tabase(Speir et al., 2016). Intergenic peaks were defined as any non-promoter or non-intragenic peaks, and were assigned to the
gene of the nearest TSS based on the distance from the start of the peak. Priority was given to transcripts that were canonical, based
on the UCSC Known Canonical database.
For IRF9-ChIP, paired-end reads were mapped to the Mus musculus genome (mm10 assembly) using Bowtie2 (v2.3.2) with
parameters –no-unal -X 500 –no-mixed –no-discordant. Concordantly aligned paired mates were used for individual peak
calling and pooled replicate peak calling by MACS2 with the arguments ‘‘–nomodel –shift 100 –extsize 200 -p 0.2 -B –mfold
3 50 –SPMR –keep-dup ’auto’.’’ IDR was calculated using custom bash scripts on all pairs of individual replicate peak lists
against the oracle peak list of pooled replicates. Reproducible peaks were thresholded for those showing IDR < 0.01 and
used for further analysis.
Gene tracks were generated by converting BAM files to bigWig files using bedtools2 (v.2.26.0)(Quinlan and Hall, 2010) and UCSC’s
bedGraphToBigWig (v.4)(Kent et al., 2010) and visualized using the Gviz R package (v.1.18.2)(Hahne and Ivanek, 2016).e5 Cell Reports 24, 1949–1957.e1–e6, August 21, 2018
Statistical Analyses
For graphs, data are shown asmean ± SEM, and unless otherwise indicated, statistical differences were evaluated using a two-tailed
unpaired Student’s t test, and Welch’s correction. Statistical differences in survival were determined by Gehan-Breslow-Wilcoxon
Test analysis. For RNA-seq data, significance cutoff was determined using multiple hypothesis corrected p values as calculated
by DESeq2. p < 0.05 was considered significant and is indicated in figures by an ‘‘*.’’ Graphs were produced and statistical analyses
were performed using GraphPad Prism.
DATA AND SOFTWARE AVAILABILITY
The accession number for all RNA-seq and ChIP-seq data reported in this paper is GEO: GSE106139.Cell Reports 24, 1949–1957.e1–e6, August 21, 2018 e6
